 BRIDGEWATER, N.J., July 28, 2020 GLOBE NEWSWIRE -- Menlo Therapeutics Inc. Nasdaq: MNLO Menlo or the Company, a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it will report its financial results for the second quarter ended June 30, 2020, on Thursday, August 6, before the market opens. Menlo will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Webcast Thursday, August 6th 8:30amET Toll Free: 800-263-0877 International: 646-828-8143 Conference ID: 2365810 Webcast: A replay of the call will be archived on the Companys website at promptly after the conference call.About Menlo Therapeutics Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. to form a different type of biopharmaceutical company working to solve some of todays most difficult therapeutic challenges in dermatology and beyond.With expertise in topical medicine innovation as a springboard, the Company is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology MSTTM, and has received FDA approval for AMZEEQ minocycline topical foam, 4, the worlds first topical minocycline, and now also for ZILXITM minocycline topical foam, 1.5, the first minocycline product of any kind to be approved by the FDA for use in rosacea.For more information about Menlo or its investigational products, visit Menlo may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Menlos website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.Media Relations: Bridgette Potratz Zeno Group 312-755-5462, x5516 Relations: Joyce Allaire LifeSci Advisors, LLC 646-889-1200 